ROLE OF ALTERATION OF CK5\6 PROFILE IN DYSPLASTIC PROGRESSION OF ORAL MUCOSA IN TOBACCO USERS
AbstractBackground: To determine staining expression of CK5\6 in healthy oral mucosa and various grades of oral dysplasia and to find out the possible association of CK5\6 expression in the dysplastic transformation of clinically normal oral mucosa to various grades of oral dysplasia. Methods: This cross-sectional descriptive study was done at Al-Tibri Medical College and Hospital and Dow University of Health Sciences, Karachi from March 2018 to November 2018. It included 120 diagnosed paraffin-embedded tissue samples of normal oral mucosa and various grades of oral epithelial dysplastic lesions. The patient’s data were reviewed for age, gender, and tobacco habits. For immunohistochemistry CK5\6 staining was performed on all the samples. Immunohistochemical evaluation was done by observing the staining expression of CK5\6 on various oral dysplastic samples on the basis of staining intensity. The compiled data were statistically analyzed by using Chi-square. p-values of <0.05 were considered to be significant. Results: All of the 60/60 (100%) oral dysplastic cases were moderate to strongly positive for CK5\6. A gradual increase in staining intensity for CK5\6 was observed with increasing grades of dysplasia. We found a highly significant association of CK5\6 immunopositivity in the transformation of normal mucosa to various grades of oral dysplastic lesions. Conclusion: CK5\6 can be used as a reliable adjuvant marker for the early dysplastic transformation of oral mucosa in tobacco users before it progresses to oral squamous cell carcinoma (OSCC).Keywords: Oral dysplastic lesions; CK5\6; Oral squamous cell carcinoma
Khan SZ, Farooq A, Masood M, Shahid AB, Irfan UK, Nisar H, et al. Smokeless tobacco use and risk of oral cavity cancer. Turk J Med Sci 2020;50(2):291–97.
White JK, Gerdin AK, Karp NA, Ryder E, Buljan M, Bussell JN, et al. Genome-wide Generation and Systematic Phenotyping of Knockout Mice Reveals New Roles for Many Genes. Cell 2013;154(2):452–64.
Miller RD. Cytokeratin 56. Propath. [Internet]. 2000. [cited 2019 May]. Available from: http://propath.org/companies/press-clippings/26-newsletters/305-cytokeratin-5-6-december-2000
Fillies T, Jogschies M, Kleinheinz J, Brandt B, Joos U, Buerger H. Cytokeratin alteration in oral leukoplakia and oral squamous cell carcinoma. Oncol Rep 2007;18(3):639–43.
Parlatescu I, Gheorghe C, Coculescu E, Tovaru S. Oral Leukoplakia - an Update. Maedica (Buhar) 2014;9(1):88–93.
Premalignant lesions. The oral cancer foundation; [Internet]. 2018. [cited 2019 May]. Available from: https://oralcancerfoundation.org/cdc/premalignant-lesions/
Frohwitter G, Guerger H, Van Diest PJ, Korsching E, Kleinheinz J, Fillies T. Cytokeratin and protein expression patterns in squamous cell carcinoma of the oral cavity provide evidence for two distinct pathogenetic pathways. Oncol Lett 2016;12(1):107–13.
Beynon RA, Lang S, Schimansky S, Chrisopher MP, Weylen A, Thomas SJ, et al. Tobacco smoking and alcohol drinking at diagnosis of head and neck cancer and all‐cause mortality: Results from head and neck 5000, a prospective observational cohort of people with head and neck cancer. Int J Cancer 2018;143(2):1–14.
Akram S, Mirza T, Aamir Mirza M, Qureshi M. Emerging Patterns in Clinico-pathological spectrum of Oral Cancers. Pak J Med Sci 2013;29(3):783–7.
Devi M, Vijayalakshmi D, Dhivya K, Vezhavendhan N. A study on awareness of early detection and screening of potentially malignant oral disorders and oral cancer. J NTR Univ Health Sci 2017;6(1):35–8.
Charan J, Biswas T. How to calculate sample size for different study designs in medical research. Indian J Psychol Med 2013;35:121–6.
Mortazavi H, Baharvand M, Mehdipour M. Oral Potentially Malignant Disorders: An Overview of More than 20 Entities. J Dent Res Dent Clin Dent Prospects 2014;8(1):6–14.
Kitamura R, Toyoshima T, Tanaka H, Kawano S, Kiyosue T, Matsubara R, et al. Association of cytokeratin 17 expression with differentiation in oral squamous cell carcinoma. J Cancer Res Clin Oncol 2012;138(8):1299–310.
Sarode SC, Sarode GS, Karmarkar S, Tupkari JV. A new classification of potentially malignant disorders of the oral cavity. Oral Oncol 2011;47(9)920–1.
Ruiter DJ, Fleuren GJ, Warnaar SO. Application of Monoclonal Antibodies in Tumor Pathology. Martinus Nijhoff Publishers. BOSTON, 2012; p.64.
Pernick N. Cytokeratins (CK) - general. Pathology Outlines. [Internet]. 2013. Cited 2019 May]. Available from: http://www.pathologyoutlines.com/topic/stainsckgeneral.html
Patil A, Patil K, Tupsakhare S, Gabhane M, Sonune S, Kandalgaonkar S. Evaluation of Podoplanin in Oral Leukoplakia and Oral Squamous Cell Carcinoma. Scientifica 2015;2015:1–6.
Mackenzie I, Gao Z. Patterns of cytokeratin expression in the epithelia of inflamed human gingiva and periodontal pockets. J Periodontal Res 1993;28(1):49–59.
Jiang Q, Yu Y, Ruan H, Luo Y, Guo X. Morphological and functional characteristics of human gingival epithelium. BMC Oral Health 2014;14(1):30.
Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 56 marker in immunohistochemistry of differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2002;116(6):823–30.
Chatterjee S. Cytokeratins in health and diseases. Oral Maxillofac Pathol J 2012:3(1);198–202.
Kasai Y, Sugiyama H, Takagi R, Kondo M, Owaki T, Namiki H, et al. Brush biopsy of human oral mucosal epithelial cells as a quality control of the cell source for fabrication of transplantable epithelial cell sheets for regenerative medicine. Regen Ther 2016;4:71–7.
Ranganathan K, Kavitha R, Sawant SS, Vaidya MM. Cytokeratin expression in oral submucous fibrosis Animmunohistochemical study. J Oral Pathol Med 2006;35(1):25–32.
Sawant S, Vaidya M, Chaukar D, Gangadaran P, Singh AK, Rajadhyax S, et al. Clinicopathological features and prognostic implications of loss of K5 and gain of K1, K8 and K18 in oral potentially malignant lesions and squamous cell carcinomas: An immunohistochemical analysis. Edorium J Tumor Biol 2014;1:1–22.